Serendipity in Cancer Drug Discovery: Rational or Coincidence?

[1]  G. Nimako,et al.  Synergistic Benefit of Statin and Metformin in Gastrointestinal Malignancies , 2017, Journal of pharmacy practice.

[2]  F. Lo‐Coco,et al.  Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. , 2015, Clinical lymphoma, myeloma & leukemia.

[3]  C. Bain,et al.  Cancers prevented in Australia in 2010 through the consumption of aspirin , 2015, Australian and New Zealand journal of public health.

[4]  R. Hills,et al.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[5]  R. Fonseca,et al.  Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. , 2015, Blood.

[6]  Y. Kakeji,et al.  Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Morgan,et al.  Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial , 2015, British journal of haematology.

[8]  T. Habermann,et al.  The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. , 2015, Blood.

[9]  R. Greil,et al.  Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up , 2015, British journal of haematology.

[10]  F. Sung,et al.  Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia , 2015, Medicine.

[11]  J. Vose,et al.  Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study , 2015, Cancer.

[12]  T. Efferth,et al.  A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer☆☆☆ , 2014, EBioMedicine.

[13]  A. Śliwińska,et al.  Metformin in cancer prevention and therapy. , 2014, Annals of translational medicine.

[14]  G. Rena,et al.  Molecular mechanism of action of metformin: old or new insights? , 2013, Diabetologia.

[15]  W. Sheu,et al.  Aspirin prevents resistin-induced endothelial dysfunction by modulating AMPK, ROS, and Akt/eNOS signaling. , 2012, Journal of vascular surgery.

[16]  Heidi Ledford.  Drug candidates derailed in case of mistaken identity , 2012, Nature.

[17]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[18]  T. Efferth,et al.  First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. , 2011, Anticancer research.

[19]  D. Schadendorf,et al.  Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model , 2011, Proceedings of the National Academy of Sciences.

[20]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[21]  G. Kobbe,et al.  Plerixafor Enables Successful Hematopoietic Stem Cell Collection in an Extensively Pretreated Patient with Testicular Cancer , 2010, Acta Haematologica.

[22]  B. Aggarwal,et al.  Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals , 2010, Cancer and Metastasis Reviews.

[23]  R. Kerbel,et al.  Raising the bar for cancer therapy models , 2010, Nature Biotechnology.

[24]  Gregory A Petsko,et al.  When failure should be the option , 2010, BMC Biology.

[25]  R. Mayer,et al.  Targeted therapy for advanced colorectal cancer--more is not always better. , 2009, The New England journal of medicine.

[26]  B. Aggarwal,et al.  Models for prevention and treatment of cancer: problems vs promises. , 2009, Biochemical pharmacology.

[27]  J. Marshall,et al.  Is levoleucovorin an alternative to racemic leucovorin? A literature review. , 2009, Clinical colorectal cancer.

[28]  Manal M. Hassan,et al.  Antidiabetic therapies affect risk of pancreatic cancer. , 2009, Gastroenterology.

[29]  D. Guertin,et al.  The Pharmacology of mTOR Inhibition , 2009, Science Signaling.

[30]  J. Byrd,et al.  Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. , 2009, Blood.

[31]  Vinod K. Sharma,et al.  Chronic arsenic toxicity from Ayurvedic medicines , 2008, International journal of dermatology.

[32]  N. Pavlidis,et al.  Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. , 2008, Critical reviews in oncology/hematology.

[33]  J. Zeldis,et al.  Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation , 2008, British journal of haematology.

[34]  P. Richardson,et al.  A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma , 2008, Therapeutics and clinical risk management.

[35]  S. Ménard,et al.  Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. , 2007, Cancer research.

[36]  V. Werth,et al.  Dermatologic therapeutics: thalidomide. A practical guide , 2007, Dermatologic therapy.

[37]  R. Nahta,et al.  Trastuzumab: triumphs and tribulations , 2007, Oncogene.

[38]  C. Lindley,et al.  Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. , 2006, Clinical therapeutics.

[39]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[40]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[41]  A. Jubb,et al.  Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Efferth,et al.  Artesunate in the treatment of metastatic uveal melanoma--first experiences. , 2005, Oncology reports.

[43]  A. Dachman,et al.  Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Franceschi,et al.  Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice , 2005, Experimental Gerontology.

[45]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[47]  A. Oza,et al.  A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. , 2005, European journal of cancer.

[48]  G. Mufti,et al.  Thalidomide therapy for low-risk Myelodysplasia. , 2005, Leukemia research.

[49]  R. Vigneri,et al.  Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells , 1982, Diabetologia.

[50]  W. Bollag,et al.  Tumour inhibitory effects of a new class of cytotoxic agents: Methylhydrazine derivatives , 1963, Experientia.

[51]  Roger B. Davis,et al.  Heavy metal content of ayurvedic herbal medicine products. , 2004, JAMA.

[52]  D. Piwnica-Worms,et al.  CXCR4 Regulates Growth of Both Primary and Metastatic Breast Cancer , 2004, Cancer Research.

[53]  Dominique Schols,et al.  Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.

[54]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[55]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[56]  C. Day,et al.  Metformin: its botanical background , 2004 .

[57]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[58]  J. Dipersio,et al.  Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  R. Pazdur,et al.  United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.

[60]  Keunchil Park,et al.  Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma , 2004, Investigational New Drugs.

[61]  J. Vane,et al.  The mechanism of action of aspirin. , 2003, Thrombosis research.

[62]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[63]  S. Baudet,et al.  Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. , 2003, Blood.

[64]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[65]  B. Aggarwal,et al.  Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester1 , 2002, The Journal of Immunology.

[66]  U. Germing,et al.  Thalidomide for the treatment of patients with myelodysplastic syndromes , 2002, Leukemia.

[67]  J. Isola,et al.  Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.

[68]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[69]  X. Ding,et al.  Prevention of pancreatic cancer induction in hamsters by metformin. , 2001, Gastroenterology.

[70]  K. Antman,et al.  Introduction: the history of arsenic trioxide in cancer therapy. , 2001, The oncologist.

[71]  T D Stephens,et al.  Mechanism of action in thalidomide teratogenesis. , 2000, Biochemical pharmacology.

[72]  Jacob,et al.  Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID‐enteropathy in the rat , 2000, Alimentary pharmacology & therapeutics.

[73]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[74]  P. G. Wells,et al.  Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity , 1999, Nature Medicine.

[75]  V. Diehl,et al.  Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. , 1998, Blood.

[76]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.

[77]  G. Morgant,et al.  Synthesis and antitumor activity of the metformin platinum (IV) complex. Crystal structure of the tetrachloro(metformin)platinum (IV) dimethylsulfoxide solvate. , 1997, Journal of inorganic biochemistry.

[78]  M. Dimopoulos,et al.  Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. , 1997, The Journal of urology.

[79]  Y. Kwong,et al.  Delicious poison: arsenic trioxide for the treatment of leukemia. , 1997, Blood.

[80]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[81]  A. Chevallier.  Encyclopedia of Medicinal Plants , 2016 .

[82]  E. De Clercq,et al.  Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. , 1996, The Journal of infectious diseases.

[83]  S. Meshnick,et al.  The mode of action of the antimalarial artemisinin and its derivatives. , 1996, General pharmacology.

[84]  J. McDougall,et al.  Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. , 1995, Cancer letters.

[85]  A. Fitton,et al.  Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. , 1995, Drugs.

[86]  V. Souliotis,et al.  Differential effects of procarbazine and methylnitrosourea on the accumulation of O6-methylguanine and the depletion and recovery of O6-alkylguanine-DNA alkyltransferase in rat tissues. , 1994, Carcinogenesis.

[87]  Aronson Sm.  Arsenic and old myths. , 1994 .

[88]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A. Endo,et al.  The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.

[90]  X. Yue,et al.  [Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro]. , 1992, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[91]  E. De Clercq,et al.  Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[92]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[93]  M. Ciampolini,et al.  Dinickel and dicopper complexes with N,N-linked bis(cyclam) ligands. An ideal system for the investigation of electrostatic effects on the redox behavior of pairs of metal ions , 1987 .

[94]  D. Brahams.  The evils of delay. , 1987, Lancet.

[95]  L. Matherly,et al.  Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates. , 1987, NCI monographs : a publication of the National Cancer Institute.

[96]  R. Defendini,et al.  Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1985, The Journal of clinical investigation.

[97]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[98]  S. Sehgal,et al.  Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.

[99]  W. Maltese.  Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1984, Biochemical and biophysical research communications.

[100]  D. Houchens,et al.  Human brain tumor xenografts in nude mice as a chemotherapy model. , 1983, European journal of cancer & clinical oncology.

[101]  J. Cassady,et al.  An evaluation of long‐term survival and treatment complications in children with Hodgkin's disease , 1983, Cancer.

[102]  R. Gelman,et al.  Phase II trials of baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5‐fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer , 1981, Cancer.

[103]  J. Douros,et al.  New antitumor substances of natural origin. , 1981, Cancer treatment reviews.

[104]  V. Tomasi,et al.  Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. , 1980, British Journal of Cancer.

[105]  M. Brown,et al.  Inhibition of cholesterol synthesis with compactin renders growth of cultured cells dependent on the low density lipoprotein receptor. , 1979, The Journal of biological chemistry.

[106]  D. Isherwood,et al.  EFFECT OF ASPIRIN ON INCIDENCE OF PRE-ECLAMPSIA , 1979, The Lancet.

[107]  R. Goodlin,et al.  ASPIRIN FOR THE TREATMENT OF RECURRENT TOXÆMIA , 1978, The Lancet.

[108]  I. Kaneko,et al.  Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. , 1978, European journal of biochemistry.

[109]  M. Beaven,et al.  Antiproliferative activity of anti-inflammatory drugs in two mammalian cell culture lines. , 1977, The Journal of pharmacology and experimental therapeutics.

[110]  R. Martel,et al.  Inhibition of the immune response by rapamycin, a new antifungal antibiotic. , 1977, Canadian journal of physiology and pharmacology.

[111]  V. Hial,et al.  Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. , 1976, European journal of pharmacology.

[112]  Steer Pj.  Letter: Obstetric delivery today. , 1976, Lancet.

[113]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[114]  A. Krishan,et al.  Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts , 1975, The Journal of cell biology.

[115]  G. Bonadonna,et al.  Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.

[116]  E. Boldrey,et al.  Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors , 1975, Cancer.

[117]  J. Hanley,et al.  Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-THIOGUANINE (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel. , 1975, Cancer chemotherapy reports.

[118]  E. Freis,et al.  RAUWOLFIA DERIVATIVES AND CANCER , 1974 .

[119]  P. Cooper.  What will reorganisation do for the patient , 1974 .

[120]  P C Elwood,et al.  A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial Infarction , 1974, British medical journal.

[121]  T. Powles,et al.  Anti-metastatic effect of aspirin. , 1973, Lancet.

[122]  H. Stähblin,et al.  Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors. , 1973, European journal of cancer.

[123]  G. Neil,et al.  Antileukemic activity of streptozotocin (NSC-85998) and its analogs. , 1972, Cancer chemotherapy reports.

[124]  E. Mansour,et al.  HÆMATOLOGICAL EFFECTS OF ASPIRIN , 1972 .

[125]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[126]  A. Eddleston,et al.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. , 1968, Lancet.

[127]  L. Opie,et al.  Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. , 1968, Lancet.

[128]  Evans Js,et al.  Antitumor and hyperglycemic activity of streptozotocin (NSC-37917) and its cofactor, U-15,774. , 1965 .

[129]  I. Todd.  Natulan in Management of Late Hodgkin's Disease, Other Lymphoreticular Neoplasms, and Malignant Melanoma , 1965, British medical journal.

[130]  G. Mathé,et al.  METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HAEMATOSARCOMA AND LEUKAEMIA. , 1963, Lancet.

[131]  R. Trussell,et al.  Carcinoma of the cervix treated with continuous intra-arterial methotrexate and intermittent intramuscular leucovorin. , 1961, Lancet.

[132]  A. Dietz,et al.  Streptozotocin, a new antibacterial antibiotic. , 1959, Antibiotics annual.

[133]  R L NOBLE,et al.  ROLE OF CHANCE OBSERVATIONS IN CHEMOTHERAPY: VINCA ROSEA * , 1958, Annals of the New York Academy of Sciences.

[134]  F. M. Huennekens,et al.  Inhibition of Dihydrofolic Reductase by Aminopterin and Amethopterin.∗ † , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[135]  E. Greenspan,et al.  Reversal of aminopterin and amethopterin toxicity by citrovorum factor. , 1950, Journal of the American Medical Association.

[136]  T. Jukes,et al.  Prevention of Chemotherapeutic Effects of 4-Amino-N10-Methyl-Pteroyl-glutamic Acid on Mouse Leukemia by Citrovorum Factor.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[137]  C. A. Nichol,et al.  Synthesis of Citrovorum Factor From Folic Acid By Liver Slices; Augmentation By Ascorbic Acid.∗ , 1950, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[138]  Heinle Rw,et al.  Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. , 1948 .

[139]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[140]  M. L. King,et al.  The Similarity of the Effect of Podophyllin and Colchicine and Their Use in the Treatment of Condylomata Acuminata. , 1946, Science.

[141]  O. Culp,et al.  Condylomata Acuminata: Two Hundred Cases Treated With Podophyllin. , 1944, Annals of surgery.

[142]  C. Forkner,et al.  ARSENIC AS A THERAPEUTIC AGENT IN CHRONIC MYELOGENOUS LEUKEMIA: PRELIMINARY REPORT , 1931 .

[143]  C. Watanabe.  STUDIES IN THE METABOLISM CHANGES INDUCED BY ADMINISTRATION OF GUANIDINE BASES I. INFLUENCE OF INJECTED GUANIDINE HYDROCHLORIDE UPON BLOOD SUGAR CONTENT , 1918 .

[144]  R. Williamson.  On the TREATMENT of GLYCOSURIA and DIABETES MELLITUS with ASPIRIN , 1902, British medical journal.

[145]  E. Bradford,et al.  Action of Iron, Cod-liver Oil, and Arsenic on the Globular Richness of the Blood , 1878 .